Emerald Health signs Lonza to manufacture cannabinoid API

Emerald Health Pharmaceuticals signed a contract with Lonza to manufacture its synthetic cannabinoid derivative VCE-004.8, including API in Nansha, China, hard capsules in Edinburgh, Scotland, and soft gels in Ploermel, France.

“Emerald Health Pharmaceuticals has signed Lonza to make a synthetic derivative of cannabidiol it is developing to treat multiple sclerosis and systemic scleroderma.”doi.org

• 1 source
• doi.orgLonza is picked for cannabinoid synthesisRick MullinFeb 17, 2019

Summarized from public sources; check the original articles before acting on it.